Alpha Teknova, Inc. (TKNO)

Market Cap	260.62M
Revenue (ttm)	38.92M
Net Income (ttm)	-21.50M
Shares Out	53.52M
EPS (ttm)	-0.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	150,223
Open	4.860
Previous Close	4.780
Day's Range	4.860 - 4.960
52-Week Range	3.450 - 10.370
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2025

About TKNO

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug di...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Jun 25, 2021
• Employees: 173
• Stock Exchange: NASDAQ
• Ticker Symbol: TKNO
• Website: https://www.teknova.com

Financial Performance

In 2024, Alpha Teknova's revenue was $37.75 million, an increase of 2.89% compared to the previous year's $36.68 million. Losses were -$26.75 million, -27.28% less than in 2023.